| Name | Title | Contact Details |
|---|
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
MedMen Enterprises is a leading cannabis company in the U.S. with assets and operations nationwide. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing and retail, and is the most recognized cannabis brand in the world today. MedMen brings class leading operational expertise and unprecedented investment to the fast changing and fast-growing cannabis industry as it moves from its gray market legacy to a fully regulated, legitimate and commercially viable market. Based in Los Angeles, MedMen employs over 1,100 team members across the U.S. It was founded in 2010 by Adam Bierman and Andrew Modlin, two visionary entrepreneurs who saw not just a tremendous business opportunity in the growing legalization of marijuana, but a chance to redefine our society`s relationship with cannabis. The federal prohibition has had a disastrous impact, overpopulating our prisons and enriching violent drug cartels while keeping a relatively benign substance with proven benefits out of the reach of law abiding citizens. MedMen supports sensible, clear and just drug laws that strengthen communities and create economic opportunities. The company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates.
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.
Omega Protein Corporation was a publicly traded US company, founded in 1913 as a fishing operation.
Our mission is to champion healthy communities by providing affordable, compassionate, and high-quality care.